BACKGROUND: Both unfractionated heparin (UFH) and low-molecular-weight heparin (LMWH) are approved for venous thromboembolism (VTE) prophylaxis. Which agent is superior remains controversial.

Tinzaparin is a low-molecular-weight heparin (LMWH) with antithrombotic properties. It has FDA-approved labeling for use in the treatment of acute symptomatic deep-vein thrombosis (DVT ...

Low molecular weight heparin (LMWH) is an anticoagulant injected subcutaneously or intravenously and acts via activation of antithrombin III which in turn inactivates thrombin and factor Xa to ...

There are two formulations of heparins, unfractionated heparin (UFH) and low molecular weight heparin (LMWH), used in clinical practice. Unfractionated heparin is used for both therapeutic ...

Key developments include fractionated and low-molecular-weight heparin for thrombosis management. The global heparin market is projected to rise by $3.34b by 2028 at an annual growth rate of 7.22% ...

Unfractionated heparin, low-molecular-weight heparin (enoxaparin or fondaparinux) or bivalirudin may be used; unfractionated heparin should be given for 48 hours total and low molecular weight ...

In addition, the market is driven by developments in heparin formulations, particularly fractionated and low-molecular-weight variants for thrombosis management. Key patient groups include the ...

Routine heparinization might reduce the likelihood of renal allograft thrombosis, but some investigators claim that this approach increases morbidity without exerting beneficial effects.